AUTHOR=Chen Yinong , Yin Chun , Li Qing , Yu Luyao , Zhu Longyang , Hu Dayi , Sun Yihong 

TITLE=Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.720113

DOI=10.3389/fcvm.2021.720113

ISSN=2297-055X

ABSTRACT=<p><bold>Background:</bold> The value of aspirin for primary prevention continues to be debated. Data showing whether aspirin use for primary prevention adheres to established guidelines in real world practice are sparse.</p><p><bold>Methods:</bold> A total of 13,104 patients without cardiovascular diseases (CVD) were selected from the DYS-lipidemia International Study of China, a national survey of patients with dyslipidemia in 2012. The CVD risk of the participants were calculated using the 10-year risk of Ischemic Cardiovascular Diseases model. The misuse of aspirin for primary prevention was defined as having CVD risk &lt;10% with daily aspirin. Multivariate logistic regression models were used to explore risk factors associated with aspirin misuse.</p><p><bold>Results:</bold> The proportion of the patients categorized as low, moderate and high risk for CVD were 52.9, 21.6, and 25.4% respectively. The misuse frequency of aspirin was 31.0% (2,147/6,933) in patients with low risk. The misuse of aspirin increased with aging for both men and women. In the multivariate analysis, the independent risk factors associated with aspirin misuse were hypertension, diabetes mellitus, a family history of premature CVD, and elderly age. Level of total cholesterol is negatively associated with aspirin misuse. Patients from low level hospitals are more likely to be taking aspirin inappropriately. Results remained consistent after including 2,837 patients having 10-year risk for CVD between 10 and &lt;20%.</p><p><bold>Conclusion:</bold> The misuse of aspirin for primary prevention is common in patients having CVD risk &lt;10%. There are important opportunities to improve evidence-based aspirin use for the primary prevention of CVD in Chinese patients.</p><p><bold>Clinical Trial Registration:</bold><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/</ext-link>, identifier [NCT01732952].</p>